Vertex Pharmaceuticals Inc (VRTX)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	3,619,600	3,469,700	3,364,900	3,259,700	3,322,000	3,273,200	3,194,600	2,451,100	2,342,100	2,176,190	1,991,724	2,761,994	2,711,647	2,690,691	2,080,775	1,510,932	1,176,810	2,144,106	2,215,334	2,155,267
Total assets	US$ in thousands	22,730,200	21,726,200	20,349,200	18,974,200	18,150,900	16,706,400	15,582,200	14,256,100	13,432,500	12,618,700	12,221,700	12,115,100	11,751,800	11,301,600	10,216,400	8,893,200	8,318,460	7,514,550	7,033,470	6,543,110
ROA		15.92%	15.97%	16.54%	17.18%	18.30%	19.59%	20.50%	17.19%	17.44%	17.25%	16.30%	22.80%	23.07%	23.81%	20.37%	16.99%	14.15%	28.53%	31.50%	32.94%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $3,619,600K ÷ $22,730,200K
= 15.92%

Vertex Pharmaceuticals, Inc. has shown a decreasing trend in return on assets (ROA) over the past eight quarters. The ROA declined from 18.30% in Q4 2022 to 15.92% in Q4 2023. The company's ROA peaked at 20.50% in Q2 2022 and has since been on a downward trajectory. This downward trend may indicate challenges in efficiently utilizing its assets to generate profits. It is essential for Vertex Pharmaceuticals to closely monitor and improve its management of assets to enhance its profitability and long-term financial performance.